Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 746

Sort by

Sort Order Select

Journal Articles

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Amandeep Kaur, PhD, Katherine M Hannan, PhD, Samina Nazir, MSc, Kylee H Maclachlan, FRACP,FRCPA, Gretchen Poortinga, PhD, Si Ming Man, PhD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Ross D Hannan, PhD, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 2360.

https://doi.org/10.1182/blood-2019-121713

Published: 2019

Journal Articles

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Melissa Castiglione, BS, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 2485.

https://doi.org/10.1182/blood-2019-131074

Published: 2019

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

Aurelie Baudet, PhD, Karolina Paulina Komorowska, PhD, Hultmark Simon, MS, Marcus Järås, PhD, Marion Chapellier, PhD, Gunnar Juliusson, MD PhD, Mattias Magnusson, PhD

Blood (2019) 134 (Supplement_1): 2466.

https://doi.org/10.1182/blood-2019-122661

Published: 2019

Journal Articles

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

Blood (2019) 134 (Supplement_1): 2375.

https://doi.org/10.1182/blood-2019-129200

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Mohamed A Yassin, MBBS, MSc, Rola S Ghasoub, BSC, Mahmood B Aldapt, MD, Mohammad Abdul-Jaber Abdulla, MD, Prem Chandra, PhD, Hawraa M Shwaylia, MD, Abdulqadir Jeprel Nashwan, BSN, MSN, Nancy Kassem, BSC, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5907.

https://doi.org/10.1182/blood-2019-121827

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia

Rong Fu, Jr., PhD, Shaoxue Ding, MD, Chunyan Liu, Bingnan Liu, Hui Liu, Liu Zhaoyun, Tong Chen, MD, Tian Zhang, Zonghong Shao, MD, Ting Wang

Blood (2019) 134 (Supplement_1): 3747.

https://doi.org/10.1182/blood-2019-127769

Published: 2019

Journal Articles

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 3750.

https://doi.org/10.1182/blood-2019-132220

Published: 2019

Journal Articles

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Keith W. Pratz, MD, Andrew H. Wei, Daniel A Pollyea, MD, Brian A Jonas, MD PhD, Walter Fiedler, MD, Christian Recher, MD PhD, Wan-Jen Hong, MD, Jalaja Potluri, MD, Catherine Miller, PharmD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3897.

https://doi.org/10.1182/blood-2019-127423

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Mariana Bastos-Oreiro, MD PhD, Nieves Lopez, Pilar Gomez, Liébana Marta, Laura LLorente, MD, Antonio Gutiérrez, EVA Domingo Domenech, PhD, Maria Jesus Vidal Maceñido, MD, Raquel Del Campo, Leyre Bento, Daniel Garcia, Miriam Santero, Jaime Perez De Oteyza, MD PhD, Belén Navarro, MD, Antonia Rodriguez Izquierdo, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4040.

https://doi.org/10.1182/blood-2019-125813

Published: 2019

Journal Articles

Virological and Immunological Monitoring of Human Cytomegalovirus (HCMV) Infection in Hematopoietic Stem Cell Transplantation Recipients (HSCTR)

Elisa Gabanti, Roberta Sciarra, MD, Oscar Borsani, MD, Giuseppe Gerna, Daniela Caldera, MD, Anna Amelia Colombo, MD, Emilio Paolo Alessandrino, MD, Paolo Bernasconi, MD, Daniele Lilleri

Blood (2019) 134 (Supplement_1): 4544.

https://doi.org/10.1182/blood-2019-129939

Published: 2019

Journal Articles

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Blood (2019) 134 (Supplement_1): 4455.

https://doi.org/10.1182/blood-2019-127480

Published: 2019

Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi

Blood (2019) 134 (Supplement_1): 4314.

https://doi.org/10.1182/blood-2019-125356

Published: 2019

Journal Articles

Molecular Analysis in Patients with Idiopathic Erythrocytosis

Katarzyna Aleksandra Jalowiec, Naomi A. Porret, PhD, Raphael Joncourt, Alicia Rovo

Blood (2019) 134 (Supplement_1): 2230.

https://doi.org/10.1182/blood-2019-128169

Published: 2019

Journal Articles

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Caitlin R. Rausch, PharmD, Courtney D. DiNardo, MDMSc, Abhishek Maiti, MBBS, Nadya Jammal, PharmD, Tapan M. Kadia, MD, Kayleigh Marx, PharmD, Gautam M. Borthakur, MD, J Michael Savoy, PharmD, Naveen Pemmaraju, MD, Adam Dipippo, PharmD, Naval G. Daver, MD, Serena Chew, PharmD, Koji Sasaki, MD, Ghayas C. Issa, MD, Kiran Naqvi, MDMPH, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2640.

https://doi.org/10.1182/blood-2019-131988

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Virological and Immunological Monitoring of Human Cytomegalovirus (HCMV) Infection in Hematopoietic Stem Cell Transplantation Recipients (HSCTR)

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Molecular Analysis in Patients with Idiopathic Erythrocytosis

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only